---
title: "Hims & Hers Health (NYSE:HIMS)  Shares Down 0.9%   - Here's What Happened"
description: "Hims & Hers Health (NYSE:HIMS) shares fell 0.9% to $34.07, with trading volume down 41% from average levels. Analysts have mixed ratings, with Citigroup maintaining a \"sell\" at $27, while Canaccord Ge"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/231039877.md"
published_at: "2025-03-07T19:42:30.000Z"
---

# Hims & Hers Health (NYSE:HIMS)  Shares Down 0.9%   - Here's What Happened

> Hims & Hers Health (NYSE:HIMS) shares fell 0.9% to $34.07, with trading volume down 41% from average levels. Analysts have mixed ratings, with Citigroup maintaining a "sell" at $27, while Canaccord Genuity raised their target to $68 with a "buy" rating. The company reported Q4 earnings of $0.11 EPS, surpassing estimates, but revenue of $481.14 million fell short of expectations. Insider trading activity included sales by Soleil Boughton and Michael Chi, with 17.71% of shares held by insiders. Hims & Hers has a market cap of $7.97 billion and an average target price of $37.23.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) traded down 0.9% on Friday . The stock traded as low as $33.22 and last traded at $34.07. 7,643,464 shares changed hands during trading, a decline of 41% from the average session volume of 13,064,865 shares. The stock had previously closed at $34.39.

Get **Hims & Hers Health** alerts:

## Analyst Ratings Changes

-   Missed the Hims & Hers Rally? Clover Health Could Be Next

HIMS has been the subject of several recent research reports. Citigroup reissued a "sell" rating and set a $27.00 price target on shares of Hims & Hers Health in a report on Thursday. Canaccord Genuity Group increased their target price on shares of Hims & Hers Health from $38.00 to $68.00 and gave the stock a "buy" rating in a report on Wednesday, February 19th. Morgan Stanley cut shares of Hims & Hers Health from an "overweight" rating to an "equal weight" rating and raised their target price for the stock from $42.00 to $60.00 in a research note on Tuesday, February 18th. BTIG Research initiated coverage on shares of Hims & Hers Health in a research report on Tuesday, January 7th. They issued a "buy" rating and a $35.00 price target for the company. Finally, Leerink Partners increased their price objective on shares of Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a research note on Tuesday, February 25th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Hims & Hers Health presently has an average rating of "Hold" and an average target price of $37.23.

**Read Our Latest Stock Analysis on HIMS**

## Hims & Hers Health Stock Performance

-   Wall Street’s Most Wanted: 2 Highly Shorted Stocks Right Now

The firm has a market capitalization of $7.97 billion, a PE ratio of 81.33 and a beta of 1.37. The company has a fifty day moving average price of $37.45 and a 200-day moving average price of $27.31.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million. On average, equities analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

## Insider Activity

-   MarketBeat Week in Review – 02/17 - 02/21

In other news, insider Soleil Boughton sold 4,152 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $60.69, for a total transaction of $251,984.88. Following the transaction, the insider now directly owns 157,345 shares of the company's stock, valued at approximately $9,549,268.05. This trade represents a 2.57 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Michael Chi sold 7,259 shares of Hims & Hers Health stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $32.25, for a total value of $234,102.75. Following the sale, the insider now directly owns 184,947 shares of the company's stock, valued at approximately $5,964,540.75. This trade represents a 3.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,062,011 shares of company stock valued at $36,892,724. 17.71% of the stock is currently owned by company insiders.

## Institutional Trading of Hims & Hers Health

Institutional investors and hedge funds have recently made changes to their positions in the company. Creative Planning increased its position in Hims & Hers Health by 18.1% during the 3rd quarter. Creative Planning now owns 25,925 shares of the company's stock valued at $478,000 after purchasing an additional 3,979 shares during the period. Robeco Institutional Asset Management B.V. purchased a new position in Hims & Hers Health during the third quarter valued at approximately $604,000. QRG Capital Management Inc. increased its holdings in Hims & Hers Health by 3.9% during the third quarter. QRG Capital Management Inc. now owns 162,029 shares of the company's stock valued at $2,985,000 after buying an additional 6,077 shares during the period. Olympiad Research LP bought a new position in Hims & Hers Health in the third quarter worth approximately $262,000. Finally, Principal Financial Group Inc. lifted its holdings in Hims & Hers Health by 102.0% during the third quarter. Principal Financial Group Inc. now owns 290,414 shares of the company's stock worth $5,349,000 after buying an additional 146,621 shares during the period. 63.52% of the stock is currently owned by institutional investors.

## About Hims & Hers Health

(Get Free Report)

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

## Featured Stories

-   Five stocks we like better than Hims & Hers Health
-   Special Purpose Acquisition Company (SPAC) What You Need to Know
-   Is Myers Industries Poised for a Breakout?
-   Low PE Growth Stocks: Unlocking Investment Opportunities
-   Is BigBear.ai's 25% Plunge a False Alarm or Fire Sale?
-   Stock Market Upgrades: What Are They?
-   Broadcom Confirmed Its AI Outlook: Stock to Hit New Highs Soon

*This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.*

## Should You Invest $1,000 in Hims & Hers Health Right Now?

Before you consider Hims & Hers Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims & Hers Health wasn't on the list.

While Hims & Hers Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

### Related Stocks

- [HIMS.US - Hims & Hers Health](https://longbridge.com/en/quote/HIMS.US.md)
- [C.US - Citigroup](https://longbridge.com/en/quote/C.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 美股夜盘异动：Hims & Hers Health 夜盘跌 14.07%，FDA 调查与减肥药停供重创投资者信心 | Hims & Hers Health 夜盘跌 14.07%；西维斯夜盘跌 0.29%，成交额达到 1.16 万美元；达维塔保健夜盘跌 0.59%，成交额达到 2240 美元；Nano-X Imaging 夜盘涨 0.41%，成交额达到 13 | [Link](https://longbridge.com/en/news/275249378.md) |
| 期权热点｜周四 HIMS 大涨 5%，部分看涨期权飙升 242% | 美东时间 01 月 22 日，HIMS 期权总成交 109439 张，看涨期权占比 74%，看跌期权占比 25%。 | [Link](https://longbridge.com/en/news/273462660.md) |
| 期权热点｜周二 HIMS 大跌 10%，部分看跌期权飙升 154% | 美东时间 02 月 10 日，HIMS 期权总成交 200580 张，看涨期权占比 60%，看跌期权占比 39%。 | [Link](https://longbridge.com/en/news/275549522.md) |
| Hims & Hers Health Inc 是在获得市场支持还是在失去市场支持？ | Hims & Hers Health Inc (NYSE:HIMS) 的空头头寸增加了 6.24%，目前有 7676 万股被卖空，占可用股份的 41.71%。交易者平均需要 4.37 天来平仓这些头寸。空头头寸的上升可能表明投资者的看跌情绪 | [Link](https://longbridge.com/en/news/276248796.md) |
| 期权热点｜周一 HIMS 大跌 16%，部分看跌期权飙升 712% | 美东时间 02 月 09 日，HIMS 期权总成交 459820 张，看涨期权占比 55%，看跌期权占比 44%。 | [Link](https://longbridge.com/en/news/275400640.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
